Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Orrstown Financial Services Inc.

Orrstown Financial Services Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,484 shares of the biopharmaceutical company’s stock after selling 220 shares during the quarter. Orrstown Financial Services Inc.’s holdings in Gilead Sciences were worth $322,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the business. Algert Global LLC purchased a new position in Gilead Sciences during the second quarter worth $254,000. Creative Planning boosted its position in shares of Gilead Sciences by 8.4% in the second quarter. Creative Planning now owns 188,594 shares of the biopharmaceutical company’s stock worth $12,939,000 after buying an additional 14,544 shares during the period. Magnolia Capital Advisors LLC acquired a new stake in Gilead Sciences in the second quarter valued at approximately $461,000. Sunbelt Securities Inc. increased its stake in Gilead Sciences by 35.1% during the 2nd quarter. Sunbelt Securities Inc. now owns 15,678 shares of the biopharmaceutical company’s stock worth $1,076,000 after buying an additional 4,075 shares during the period. Finally, Quarry LP acquired a new position in shares of Gilead Sciences in the second quarter worth about $43,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock worth $42,130,461 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 1.6 %

Shares of NASDAQ GILD traded up $1.54 during mid-day trading on Wednesday, hitting $95.39. The company had a trading volume of 666,882 shares, compared to its average volume of 6,498,963. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a 50-day simple moving average of $92.00 and a two-hundred day simple moving average of $85.44. The company has a market capitalization of $118.89 billion, a PE ratio of 1,058.96, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the business posted $2.29 EPS. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on GILD shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Truist Financial upped their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Oppenheimer upped their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Finally, Wolfe Research began coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.